GleamWall
中文EN

KURA Kura Oncology, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1422143 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-35.0%
TTM EPS YoY-33.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-394.3%
Net margin-369.3%
FCF margin-112.4%
EBITDA margin-392.5%

Returns

ROE-224.9%
ROA-48.2%
ROIC (approx.)-389.8%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets96.8%
Debt / equity0.55x
Current ratio3.60x
Interest coverage-227.12x

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-34.1%
Payout ratio—
Capex / revenue4.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$67.48M$53.88M
R&D expense$251.07M$169.97M
SG&A expense$119.98M$77.11M
Operating income-$303.63M-$193.19M
Interest expense$1.51M$1.62M
Pretax income-$278.37M-$171.97M
Income tax$297,000$2.02M
Net income-$278.67M-$173.98M
EBITDA-$302.60M-$192.35M
EPS (basic)-3.18-2.02
EPS (diluted)-3.18-2.02
Weighted avg. shares (diluted)87.68M86.16M
Balance sheet
Cash & equivalents$149.10M$224.46M
Short-term investments$518.14M$502.93M
Receivables$8.80M$2.06M
Inventory$413,000$0
Current assets$708.66M$744.83M
PP&E, net$7.86M$1.68M
Total assets$738.36M$760.16M
Current liabilities$116.97M$78.71M
Short-term debt$0$2.61M
Long-term debt$9.71M$6.92M
Total debt$9.71M$9.52M
Total liabilities$564.23M$346.52M
Shareholders' equity$174.13M$413.64M
Net debt-$139.39M-$214.94M
Shares outstanding87.86M78.23M
Cash flow statement
Operating cash flow-$64.06M$134.32M
Capital expenditure$6.64M$472,000
Free cash flow-$70.70M$133.84M
Investing cash flow-$13.10M-$101.59M
Financing cash flow$1.79M$154.42M
Depreciation & amortization$1.03M$848,000
Stock-based compensation$37.11M$33.90M

Free plan shows the latest 2 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.